Axcella Health is a US-based biotechnology company that aims to treat complex diseases and improve health through its endogenous metabolic modulator compositions. It is currently undergoing clinical trials for its lead product candidates, AXA1665 and AXA1125, for reducing the risk of hepatic encephalopathy recurrence and treating non-alcoholic steatohepatitis and Long COVID therapy. Formerly known as Newco LS16 Inc, the company was founded in 2008 and is headquartered in Cambridge, Massachusetts.